(Q35056066)

6 August 2017

1 reference

title

Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? (English)

1 reference

6 August 2017

1 reference

1 reference

Richardson DR

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

235-245

1 reference

Deciphering the cause of Friedreich ataxia

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Molecular pathogenesis of Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Increased iron in the dentate nucleus of patients with Friedrich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Succinylacetone, a potent inhibitor of heme biosynthesis: Effect on cell growth, heme content and δ-aminolevulinic acid dehydratase activity of malignant murine erythroleukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

The effects of inhibition of heme synthesis on the intracellular localization of iron in rat reticulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Crystal structure of human frataxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Globin Messenger-RNA Induction During Erythroid Differentiation of Cultured Leukemia Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Induction of globin mRNA accumulation by hemin in cultured erythroleukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

The release of iron and transferrin from the human melanoma cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Iron chelators as therapeutic agents for the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

p21 is a universal inhibitor of cyclin kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

A genetic approach to elucidating eukaryotic iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.235

10.1517/13543784.12.2.235

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference